Reversible Porphobilinogen Deaminase Inhibitors for Congenital Erythropoietic Porphyria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for congenital erythropoietic porphyria (CEP) lack effectiveness and specificity in inhibiting porphobilinogen deaminase, leading to undesirable toxicity and limited treatment options, with existing inhibitors being either non-specific or causing permanent enzyme inactivation.
Innovation Solution
Development of reversible inhibitors, such as compounds of general formula (I), which non-covalently bind to the active site of porphobilinogen deaminase, reducing preuroporphyrinogen production and featuring modular structures for improved pharmacological properties and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors are used to inhibit porphobilinogen deaminase, then enzyme inhibition is achieved, but toxicity increases and specificity decreases
Solution Approach 1:
The patent changes the chemical parameters of the inhibitor molecules by using specific pyrrole and indole derivatives with defined substitution patterns (R1-R4 groups). These parameter changes in molecular structure result in selective binding to porphobilinogen deaminase with reduced off-target effects, thereby maintaining inhibition effectiveness while reducing toxicity
Solution Approach 2:
The patent creates simplified copies of the natural substrate porphobilinogen using pyrrole and indole derivatives. These copy molecules replicate the key structural features necessary for enzyme binding while modifying other aspects to reduce toxicity and improve selectivity, achieving reliable inhibition without the harmful effects of the original substrate analogs
2Reliability
If substrate analogs are used as inhibitors, then enzyme binding is achieved, but permanent inactivation occurs
Solution Approach 1:
The patent applies partial action by designing inhibitors that bind to the enzyme active site but do not completely block all enzymatic functions or cause permanent inactivation. The pyrrole and indole derivatives provide sufficient binding affinity to achieve therapeutic effect while allowing some residual enzyme activity to persist, preventing permanent inactivation
Solution Approach 2:
The patent modifies the binding parameters of the inhibitor-enzyme complex by changing the chemical structure to pyrrole and indole derivatives. These structural changes alter the interaction strength and reversibility characteristics, enabling the enzyme to maintain partial activity while still achieving effective inhibition of the pathological pathway
3Adaptability or versatility
If non-specific inhibitors are used, then broad coverage is achieved, but treatment precision decreases
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific functional groups and substitution patterns (R1-R4) that create localized regions of high affinity for porphobilinogen deaminase. The pyrrole and indole core structures with specific substituents provide precise molecular recognition at the enzyme active site, achieving treatment precision while maintaining reasonable coverage
Solution Approach 2:
The patent creates selective copies of the substrate binding interface using pyrrole and indole derivatives. These copied structures specifically mimic the interactions between porphobilinogen and porphobilinogen deaminase, providing broad coverage of the enzyme's functional sites while maintaining high specificity for the target enzyme through precise structural replication
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new inhibitors effectively reduce uroporphyrinogen I accumulation in CEP patients, offering a safer and more specific treatment option with potential for modulation, addressing the limitations of existing treatments.
Implementation Method 1
compounds of general formula (I), which non-covalently bind to the active site of porphobilinogen deaminase
Implementation Method 2
porphobilinogen deaminase (PBGD; the enzyme also known as hydroxymethylbilane synthase or uroporphyrinogen I synthase)
Implementation Method 3
uroporphyrinogen III synthase (UROIIIS), which is an enzyme of 260 residues (in the human isoform) catalyzing the cyclization of the linear tetrapyrrole hydroxymethylbilane to produce macrocycle uroporphyrinogen III
Data Source
AI summary
The invention relates to the use of a compound of general formula (I), wherein R1 and R2 are independently H or C1-C6 alkyl, or R1 and R2 are bound to one another forming an optionally substituted fused benzene ring, R3 is H, C1-C6 alkyl or —CH2— CH(NH2)—COOH and R4 is H, C1-C6 alkyl, or R4 represents (II) or (III) in the preparation of a medicinal product for treating and/or preventing congenital erythropoietic porphyria (CEP).